Overview
The goal of this clinical trial is to to evaluate the changes in retinal microvasculature secondary to intra-ocular pressure changes post intra-vitreal injection in patients with diabetic macular oedema highlighting the effect of prior anterior chamber paracentesis on such changes if present .
The main question[s]it aims to answer are:
•[is there any effect of post intra-vitreal injection IOP spikes on retinal microvasculature?] •[is there any effect of Prior Anterior Chamber Paracentesis?] Participants in group A will be subjected to an identified approved treatment( intra-vitreal injection)& Participants in group B will be subjected to a prior ACP with the intra-vitreal injection . ]
Eligibility
Inclusion Criteria:
- Patients with diabetes mellitus type II.
- Patients with visual acuity > 0.1, able to fixate and with clear visual media.
- Patients with eyes with non ischemic diffuse center involving DME were randomly assigned to receive IVI of ranibizumab either without (group A) or with (group B) ACP.
Exclusion Criteria:
- Age under 40 years.
- Poorly controlled diabetics (HbA1C greater than 9.0%)
- Proliferative diabetic retinopathy.
- OCT-Angiographic evidence of ischemia (enlarged foveal avascular zone, paramacular areas of capillary nonperfusion)
- Neovascular AMD in the study eye.
- History of glaucoma.
- Tilted disc and optic disc anomalies.
- One-eyed patients.
- Usage of systemic or topical corticosteroids.
- Patients with a history of intraocular surgery other than cataract surgery.
- Systemc diseases rather than hypertension and diabetes mellitus.
- Corneal opacities that might hinder acquisition of good quality OCT images.